“Something revolutionary is happening…” the company's website claims. “Wearable neurotechnologies that enhance sleep, alertness, and ultimately the human experience.”
or intense biotechnology “This week, a startup emerged from stealth with big plans to pioneer a new form of neurotechnology called 'electromedicine.'”
Elemind's approach is trained to continuously analyze neural activity collected by a non-invasive wearable device and deliver it through bursts of wearable neural stimulation uniquely tailored to real-time brain wave measurements. It focuses on algorithms that utilize artificial intelligence. The Cambridge, Massachusetts-based company claims its approach, based on the research of its founders, a group of distinguished scientists from MIT, Stanford, and Harvard Universities, offers a more “natural” treatment option than pharmaceuticals. There is. Neurological symptoms such as insomnia, essential tremor, and memory loss.
“Chemicals affect the entire body and often cause undesirable side effects. Elemind provides a non-chemical, direct, on-demand solution that learns and dynamically adjusts to each individual. ” said Meredith Perry, co-founder and CEO of Elemind. In the company's debut announcement. “We are the first and only company that can precisely guide and redirect brain waves in real time.”
“Elemind's first product is a general wellness device and is not subject to FDA regulation,” the company's announcement said. However, they thoroughly researched the product's potential.
To date, Elemind's technology is supported by five clinical trials and several publications in peer-reviewed scientific journals. Clinical trials have shown that Elemind's technology induces sleep up to 74% faster, significantly reduces essential tremor and improves memory with just 30 seconds of stimulation. Clinical trials have also demonstrated that Elemind can increase pain thresholds and enhance sedation. This study is currently under peer review.
“You can think of it like noise canceling for your mind,” said Dr. David Wang, CTO and co-founder of Elemind. “Our technology uses phase-locked auditory stimulation to precisely match the user's brain waves and direct them to different frequencies associated with different states.”
The Boston Globe reported that the company plans to unveil its first products in the coming months, and that the company's $12 million seed funding is an “early-stage venture fund backed by tech billionaire Jeff. It was provided by a consortium including Village Global. Bezos, Bill Gates, Reid Hoffman, and Ann Wojcicki…”
For more information, visit VentureBeat.
